secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2022-07-19T23:59:59+00:00
Accession:  0001558370-22-010821
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor dosed first patient in Phase 3 HOPE-3 trial of CAP-1002 for Duchenne MD
--------------------------------------------------------------------------------

- First patient dosed in randomized, double-blind, placebo-controlled HOPE-3 trial enrolling ~70 patients in U.S.
- CAP-1002 is a cell therapy for late-stage Duchenne muscular dystrophy; Phase 2 data showed up to 70% slowing of upper limb function loss.
- Primary endpoint is Performance of the Upper Limb 2.0; RMAT and Orphan Drug designations support regulatory pathway.
- Nippon Shinyaku partnership provides funding and commercialization rights in U.S.; Capricor holds rest-of-world rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837022010821/0001558370-22-010821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837022010821/capr-20220719x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-010821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer